Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.
Marina Frimer, MD
Advertisement
Articles by Marina Frimer, MD
Marina Frimer, MD, spoke about the goals of a phase 2 trial and how it can impact patients with platinum-sensitive recurrent uterine serous carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
3
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
